QuellTX
Marc Martinez-Llordella began their work experience as a Research Intern at the University of Geneva, Department of Cell Biology in 2003. Marc then went on to work as a Research Intern at the University of California, San Francisco in 2008. In 2010, they became a Postdoctoral Researcher at the same institution. Marc then pursued a PhD at Universitat de Barcelona, where they researched from 2004 to 2009. Marc joined the University of California, San Francisco again in 2010 as a Postdoctoral Researcher. In 2013, Marc started working at King's College London as a Lecturer, eventually becoming a Senior Lecturer in 2015 and a Visiting Senior Lecturer in 2019. Concurrently, in 2019, Marc co-founded Quell Therapeutics, where they currently hold the position of Co-founder and VP Biology.
Marc Martinez-Llordella pursued their education at the Universitat de Barcelona. Marc first completed their Bachelor of Science (BS) degree in Biology from 1999 to 2004. Following this, they pursued a Doctor of Philosophy (PhD) in Biomedicine from 2004 to 2009.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.